Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays
- PMID: 8673920
- DOI: 10.1038/nm0796-753
Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays
Abstract
Naturally occurring mutations in HIV-1-infected patients have important implications for therapy and the outcome of clinical studies. However, little is known about the prevalence of mutations that confer resistance to HIV-1 protease inhibitors in isolates derived from patients naive for such inhibitors. In the first clinical application of high-density oligonucleotide array sequencing, the sequences of 167 viral isolates from 102 patients have been determined. The DNA sequence of USA HIV-1 clade B proteases was found to be extremely variable and 47.5% of the 99 amino acid positions varied. This level of amino acid diversity is greater than that previously known for all worldwide HIV-1 clades combined (40%). Many of the amino acid changes that are known to contribute to drug resistance occurred as natural polymorphisms in isolates from patients who had never received protease inhibitors.
Similar articles
-
Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.AIDS. 2000 Jul 28;14(11):1489-95. doi: 10.1097/00002030-200007280-00004. AIDS. 2000. PMID: 10983635
-
Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.J Clin Virol. 2004 Nov;31(3):215-20. doi: 10.1016/j.jcv.2004.03.015. J Clin Virol. 2004. PMID: 15465415
-
Naturally occurring sequence polymorphisms within HIV type 1 group O protease.AIDS Res Hum Retroviruses. 2001 Nov 1;17(16):1555-61. doi: 10.1089/08892220152644269. AIDS Res Hum Retroviruses. 2001. PMID: 11709100
-
Protease inhibition in African subtypes of HIV-1.AIDS Rev. 2003 Jul-Sep;5(3):165-71. AIDS Rev. 2003. PMID: 14598565 Review.
-
Polymorphisms in HIV-1 subtype C proteases and the potential impact on protease inhibitors.Trop Med Int Health. 2008 Feb;13(2):144-51. doi: 10.1111/j.1365-3156.2007.01984.x. Trop Med Int Health. 2008. PMID: 18304259 Review.
Cited by
-
Management of Antiretroviral Therapy with Boosted Protease Inhibitors-Darunavir/Ritonavir or Darunavir/Cobicistat.Biomedicines. 2021 Mar 18;9(3):313. doi: 10.3390/biomedicines9030313. Biomedicines. 2021. PMID: 33803812 Free PMC article. Review.
-
Chip-based genotyping by mass spectrometry.Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10016-20. doi: 10.1073/pnas.96.18.10016. Proc Natl Acad Sci U S A. 1999. PMID: 10468554 Free PMC article.
-
Mutational analysis using oligonucleotide microarrays.J Med Genet. 1999 Oct;36(10):730-6. doi: 10.1136/jmg.36.10.730. J Med Genet. 1999. PMID: 10528850 Free PMC article. Review.
-
Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients.J Clin Microbiol. 2000 Nov;38(11):3919-25. doi: 10.1128/JCM.38.11.3919-3925.2000. J Clin Microbiol. 2000. PMID: 11060045 Free PMC article.
-
The role of protease inhibitor therapy in children with HIV infection.Paediatr Drugs. 2002;4(9):581-607. doi: 10.2165/00128072-200204090-00004. Paediatr Drugs. 2002. PMID: 12175273 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
